User profiles for Philip Hewitt

Phil Hewitt

Head of Investigative Toxicology, Merck Healthcare KGaA
Verified email at merckgroup.com
Cited by 4701

[HTML][HTML] Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in …

P Godoy, NJ Hewitt, U Albrecht, ME Andersen… - Archives of …, 2013 - Springer
This review encompasses the most important advances in liver functions and hepatotoxicity
and analyzes which mechanisms can be studied in vitro. In a complex architecture of nested, …

[HTML][HTML] The evolving role of investigative toxicology in the pharmaceutical industry

…, H Boonen, A Czich, G Dear, P Hewitt… - Nature reviews drug …, 2023 - nature.com
For decades, preclinical toxicology was essentially a descriptive discipline in which
treatment-related effects were carefully reported and used as a basis to calculate safety margins for …

Biomarkers for drug-induced renal damage and nephrotoxicity—an overview for applied toxicology

TC Fuchs, P Hewitt - The AAPS journal, 2011 - Springer
The detection of acute kidney injury (AKI) and the monitoring of chronic kidney disease (CKD)
is becoming more important in industrialized countries. Because of the direct relation of …

Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models

…, CE Goldring, A Guillouzo, PG Hewitt… - Nature Reviews Drug …, 2020 - nature.com
Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial pathophysiological
process that cannot yet be recapitulated in a single in vitro model. Current preclinical …

Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity

…, T Henzler, KA Matheis, T Herget, W Dekant, P Hewitt… - Toxicology, 2010 - Elsevier
Several novel urinary kidney biomarkers were recently approved by the US-FDA and EMA for
improved detection of nephrotoxicity, but few data regarding their performance are publicly …

[HTML][HTML] Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress

…, K Herrgen, P Bellwon, C Burek, GL Truisi, P Hewitt… - Journal of …, 2013 - Elsevier
High content omic techniques in combination with stable human in vitro cell culture systems
have the potential to improve on current pre-clinical safety regimes by providing detailed …

Human-induced pluripotent stem cells generate light responsive retinal organoids with variable and nutrient-dependent efficiency

…, G Hilgen, B Dorgau, L Zhu, M Yu, S Bojic, P Hewitt… - Stem Cells, 2018 - academic.oup.com
The availability of in vitro models of the human retina in which to perform pharmacological
and toxicological studies is an urgent and unmet need. An essential step for developing in …

Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry

AR Baudy, MA Otieno, P Hewitt, J Gan, A Roth… - Lab on a Chip, 2020 - pubs.rsc.org
The liver is critical to consider during drug development because of its central role in the
handling of xenobiotics, a process which often leads to localized and/or downstream tissue …

[HTML][HTML] A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity

…, RP Jones, M Elmasry, RJ Weaver, PG Hewitt… - Archives of …, 2017 - Springer
Assessing the potential of a new drug to cause drug-induced liver injury (DILI) is a challenge
for the pharmaceutical industry. We therefore determined whether cell models currently …

Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition …

…, RP Jones, E Johann, PG Hewitt… - Toxicological …, 2015 - academic.oup.com
In vitro preclinical models for the assessment of drug-induced liver injury (DILI) are usually
based on cryopreserved primary human hepatocytes (cPHH) or human hepatic tumor-derived …